Leadership Overview
Vertex has 10 executives leading key functions including strategy, research, operations, and human resources.
Driven by a commitment to scientific innovation, Vertex is dedicated to developing transformative medicines for serious diseases with significant unmet medical needs, impacting patients globally through advanced biotechnology.
Driven by a commitment to scientific innovation, Vertex is dedicated to developing transformative medicines for serious diseases with significant unmet medical needs, impacting patients globally through advanced biotechnology.
Leadership Roles at Vertex
Md Reshma Kewalramani - Chief Executive Officer & President
Md Reshma Kewalramani, the Chief Executive Officer & President at Vertex, directs the company's overarching strategy and operational execution. This leadership role involves guiding Vertex's mission to develop and commercialize medicines for serious diseases with significant unmet medical needs. Kewalramani oversees the advancement of research programs in areas such as kidney disease, type 1 diabetes, and myotonic dystrophy, ensuring alignment with the company's commitment to patient well-being. Driving innovation across the organization, the Chief Executive Officer & President ensures that Vertex maintains its position at the forefront of biotechnology. This executive's focus extends to fostering a culture of scientific excellence and strategic growth, impacting patient outcomes worldwide. By championing new therapeutic approaches, Md Reshma Kewalramani solidifies Vertex's dedication to addressing critical health challenges through groundbreaking science and patient-centric development.
Gina LaCorcia - Vice President, Chief of Staff To the Chief Executive Officer and Head of the Disease Strategy Team Program Office
Gina LaCorcia, the Vice President, Chief of Staff To the Chief Executive Officer and Head of the Disease Strategy Team Program Office at Vertex, provides critical strategic support to the Chief Executive Officer and leads the program office for disease strategy. This multifaceted role ensures that Vertex's research and development efforts are precisely aligned with the company's mission to address significant unmet medical needs. LaCorcia facilitates high-level strategic planning, oversees key cross-functional initiatives, and ensures effective communication across the executive team and research divisions. Managing the Disease Strategy Team Program Office, the Vice President, Chief of Staff To the Chief Executive Officer and Head of the Disease Strategy Team Program Office drives the focused development of therapies for critical illnesses. By enhancing strategic clarity and operational efficiency, Gina LaCorcia significantly contributes to Vertex's ability to bring life-changing medicines to patients globally.
Christina Yi - Head Chief Operating Officer, Site (Seattle)
Christina Yi, the Head Chief Operating Officer, Site (Seattle) at Vertex, spearheads the operational management and strategic development of the company's Seattle-based facilities and research initiatives. This executive role focuses on optimizing site operations to support Vertex's core mission of developing medicines for serious diseases. Yi directs the integration of cutting-edge research and development activities within the Seattle hub, ensuring seamless collaboration across scientific teams. Overseeing critical infrastructure and resource allocation, the Head Chief Operating Officer, Site (Seattle) drives efficiency and innovation within the site's operations. By fostering a dynamic research environment, Christina Yi ensures that the Seattle location significantly contributes to Vertex's global pipeline advancement, particularly in areas like genetic disorders and pain management, reinforcing the company's commitment to patient impact.
Stephanie Franklin (she/her/hers) - Senior VP & Chief Human Resources Officer, Vertex Pharmaceuticals
Stephanie Franklin (she/her/hers), the Senior VP & Chief Human Resources Officer, Vertex Pharmaceuticals at Vertex, architects the human capital strategy essential for driving scientific innovation and operational excellence. This critical role involves cultivating a high-performance culture that attracts, develops, and retains top talent across all functions, from research and development to commercial operations. Franklin ensures that Vertex's workforce is equipped with the skills and resources necessary to tackle complex medical challenges and advance the company's pipeline of transformative medicines. Overseeing global HR initiatives, the Senior VP & Chief Human Resources Officer, Vertex Pharmaceuticals champions employee engagement and fosters an inclusive environment that supports the company's mission. By aligning human resources policies with strategic business objectives, Stephanie Franklin (she/her/hers) directly contributes to Vertex's ability to deliver life-changing therapies to patients worldwide, reinforcing the organization's commitment to scientific advancement and patient care.
Colleen O'Brien - Toxicology Research Senior Scientist & Chief Revenue Officer, Study Monitor
Colleen O'Brien, the Toxicology Research Senior Scientist & Chief Revenue Officer, Study Monitor at Vertex, leads critical toxicology research initiatives and oversees study monitoring to ensure the safety and efficacy of Vertex's therapeutic candidates. This dual-focused role involves rigorous scientific investigation into potential drug effects while also ensuring the financial integrity and strategic alignment of revenue-generating activities related to research services. O'Brien's expertise in toxicology directly supports the development of medicines for serious diseases, contributing to Vertex's mission of addressing unmet medical needs. The Toxicology Research Senior Scientist & Chief Revenue Officer, Study Monitor ensures adherence to stringent regulatory standards and monitors key performance indicators for research programs. By integrating scientific depth with financial oversight, Colleen O'Brien advances Vertex's commitment to delivering safe and effective treatments to patients globally.
Sazzad Hussain - Senior Principal Scientist and Chief Revenue Officer Monitor and Associate Director
Sazzad Hussain, the Senior Principal Scientist and Chief Revenue Officer Monitor and Associate Director at Vertex, drives scientific advancement in key research areas while ensuring the effective monitoring of revenue-generating projects. This role integrates deep scientific expertise with financial oversight, crucial for advancing Vertex's mission of developing medicines for serious diseases. Hussain leads complex research initiatives, contributing to the company's pipeline in areas such as sickle cell disease and beta thalassemia. The Senior Principal Scientist and Chief Revenue Officer Monitor and Associate Director also ensures that research-related revenue streams are managed efficiently and strategically aligned with corporate goals. By bridging scientific discovery with financial acumen, Sazzad Hussain plays a vital part in Vertex's commitment to bringing transformative therapies to patients worldwide, reinforcing the company's dedication to innovation and patient outcomes.
Adila Crimi - Head To of Cell & Gene Therapy Research Chief of Staff
Adila Crimi, the Head To of Cell & Gene Therapy Research Chief of Staff at Vertex, orchestrates the strategic direction and operational execution for Vertex's cutting-edge cell and gene therapy research programs. This leadership position is pivotal in advancing the company's mission to develop transformative medicines for serious genetic disorders. Crimi ensures seamless coordination between research teams, operational functions, and executive leadership, facilitating the efficient progression of novel therapeutic candidates. Overseeing key strategic initiatives within cell and gene therapy research, the Head To of Cell & Gene Therapy Research Chief of Staff drives innovation and operational excellence. By aligning research efforts with Vertex's broader objectives, Adila Crimi significantly contributes to the company's commitment to addressing significant unmet medical needs and improving patient lives through advanced biotechnology.
Olivia Green - Director, Chief of Staff, U. S. Commercial
Olivia Green, the Director, Chief of Staff, U. S. Commercial at Vertex, directs strategic initiatives and operational enhancements within the United States commercial division. This role is critical in ensuring that Vertex's innovative therapies reach patients effectively across the U.S. market. Green collaborates closely with commercial leadership to optimize market access, sales strategies, and patient support programs, directly supporting the company's mission to serve those with serious diseases. Overseeing key projects and cross-functional alignment, the Director, Chief of Staff, U. S. Commercial drives efficiency and impact in commercial operations. By enhancing the reach and effectiveness of Vertex's commercial efforts, Olivia Green ensures that the company's life-changing medicines are accessible to the patients who need them most, reinforcing Vertex's commitment to global health.
Moira Scanlon - Director, Chief of Staff - Global Commercial Strategy
Moira Scanlon, the Director, Chief of Staff - Global Commercial Strategy at Vertex, drives the strategic planning and execution of Vertex's worldwide commercial initiatives. This executive function is essential for ensuring that Vertex's portfolio of medicines for serious diseases achieves maximum global impact. Scanlon collaborates with international commercial teams to refine market strategies, enhance product launches, and optimize patient access across diverse regions. Overseeing critical global commercial projects, the Director, Chief of Staff - Global Commercial Strategy ensures cohesive strategy implementation and operational effectiveness. By strengthening Vertex's global commercial presence, Moira Scanlon directly contributes to the company's mission of delivering transformative therapies to patients around the world, underscoring a commitment to broad patient care and scientific leadership.
Amy Longwell - Executive Assistant To Chief Human Resources Officer
Amy Longwell, the Executive Assistant To Chief Human Resources Officer at Vertex, provides essential administrative and operational support to the Chief Human Resources Officer, facilitating the smooth execution of human capital strategies. This role is integral to maintaining the efficiency of HR operations, which are crucial for supporting Vertex's mission of developing medicines for serious diseases. Longwell manages complex scheduling, coordinates key meetings, and supports the implementation of HR initiatives designed to foster a productive and engaged workforce. By ensuring the Chief Human Resources Officer can focus on strategic priorities, the Executive Assistant To Chief Human Resources Officer contributes indirectly to Vertex's overall success. This support enables the HR function to effectively manage talent and cultivate a culture that drives scientific innovation and patient-centric development across the organization.
Explore Leadership Teams in Manufacturing
Bristol-Myers Squibb operates as a global biopharmaceutical organization dedicated to discovering, developing, and manufacturing prescription medications that address serious patient needs across multiple therapeutic domains. The company's scientific expertise spans oncology, cardiovascular disease, immunoscience, and virology, with particular depth in treating complex conditions including HIV and cancer. Through sustained investment in research and development, the organization has built a comprehensive medication portfolio that combines innovative cancer immunotherapies, anticoagulant therapies, and treatments for chronic viral infections. The company's operational footprint extends across major markets worldwide, enabling efficient distribution and patient access to its therapeutic solutions. Bristol-Myers Squibb pursues a collaborative approach to medical innovation, actively engaging in research partnerships and strategic alliances that accelerate the development of new treatment options. This commitment to external collaboration complements the organization's internal capabilities, creating a dynamic environment where scientific breakthroughs can translate into meaningful therapeutic advances. Bristol-Myers Squibb's medication portfolio reflects decades of pharmaceutical expertise and a strategic focus on disease areas where unmet medical needs remain significant.
Company Leadership BG
NP
NC
Abbott is a global healthcare company that develops and delivers a broad range of medical technologies, diagnostics, nutrition products, and branded generic medicines. The company is focused on improving health outcomes and helping people live healthier lives across all stages of life. Its mission centers on creating innovative solutions that address important medical needs, including chronic disease management, cardiovascular care, diabetes care, and pain management.
Company Leadership PH
AB
SG
MW
Bharat Serums And Vaccines Limited (BSV) is one of India's fastest-growing biopharmaceutical companies, dedicated to developing a wide range of biological, biotech, and pharmaceutical products for over 50 years. The company focuses on critical therapeutic areas such as women's health, critical care, and assisted reproductive technology, aiming to improve health and save lives through innovative treatments. BSV is committed to enhancing the quality of life for patients globally, with a strong emphasis on research and development, supported by a team of over 60 scientists. As a part of the Mankind Group, BSV strives to widen accessibility to its products and deliver positive health outcomes.
Company Leadership RA
AS
Dar Al Dawa is a MENA company engaging in the pharmaceutical and consumer health industry by developing, producing, marketing and commercializing medicines and wellness products. Dar Al Dawa was established in 1975.
Company Leadership KH
MA
Frequently Asked Questions Regarding Vertex Top Executives and Leadership Team
